Conventional Radioiodine Therapy for Differentiated Thyroid Cancer

2019 ◽  
Vol 48 (1) ◽  
pp. 181-197 ◽  
Author(s):  
Dorina Ylli ◽  
Douglas Van Nostrand ◽  
Leonard Wartofsky
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy

Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer

2020 ◽  
Vol 64 (1) ◽  
Author(s):  
Ewelina Szczepanek-Parulska ◽  
Magdalena Wojewoda-Korbelak ◽  
Martyna Borowczyk ◽  
Malgorzata Kaluzna ◽  
Barbara Brominska ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Predictive Factors ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Incomplete Response

scholarly journals Radioiodine therapy reduces the frequency of circulating tumour cells in patients with differentiated thyroid cancer

2021 ◽  
Author(s):  
Mathias Schmidt ◽  
Christina Antke ◽  
Katalin Mattes‐György ◽  
Hubertus Hautzel ◽  
Stephanie Allelein ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Tumour Cells ◽  
Circulating Tumour Cells

Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer

2018 ◽  
Vol 39 (11) ◽  
pp. 969-975 ◽  
Author(s):  
Mohammad Abuqbeitah ◽  
Mustafa Demir ◽  
Levent Kabasakal ◽  
İffet Çavdar ◽  
Lebriz Uslu-Beşli ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Indirect Assessment

scholarly journals Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors

2015 ◽  
Vol 173 (3) ◽  
pp. 399-408 ◽  
Author(s):  
Hong-Jun Song ◽  
Zhong-Ling Qiu ◽  
Chen-Tian Shen ◽  
Wei-Jun Wei ◽  
Quan-Yong Luo
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Pulmonary Metastasis ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Pulmonary Metastases ◽  
Lung Metastases ◽  
Whole Body ◽  
Metastatic Node ◽  
Serum Thyroglobulin

ContextData from a large cohort of patients with pulmonary metastases from differentiated thyroid cancer (DTC) were retrospectively analyzed.ObjectiveTo assess the effect of radioiodine therapy and investigate the prognostic factors of survival for patients with pulmonary metastasis secondary to DTC.MethodsA total of 372 patients with pulmonary metastasis from DTC treated with131I entered the study. According to the results of131I whole-body scan (WBS), pulmonary metastases were classified as131I-avid and non-131I-avid. For patients with131I-avid lung metastases, treatment response was measured by three parameters: serum thyroglobulin (Tg) levels, chest computed tomography (CT) and post-therapeutic131I-WBS. Overall survival was calculated by the Kaplan–Meier method. Factors predictive of the outcome were determined by multivariate analyses.ResultsAmong patients demonstrating131I-avid pulmonary metastases (256/372, 68.8%), 156 cases (156/256, 60.9%) showed a significant decrease in serum Tg levels after131I therapy and 138 cases (138/229, 60.3%) showed a reduction in pulmonary metastases on follow-up CT. A complete cure, however, was only achieved in 62 cases (62/256, 24.2%). Multivariate analysis showed that only age, the presence of multiple distant metastases and pulmonary metastatic node size were significant independent variables between the groups of131I-avid and non-131I-avid.ConclusionThis study indicated that, most131I-avid pulmonary metastases from DTC can obtain partial or complete remission after131I therapy. Younger patients (<40 years old) with only pulmonary metastases and small (‘fine miliaric’ or micronodular) metastases appear to have relative favorite outcomes. Patients who do not respond to131I treatment have a worse prognosis.

scholarly journals Micronuclei Formation upon Radioiodine Therapy for Well-Differentiated Thyroid Cancer: The Influence of DNA Repair Genes Variants

Genes ◽  
2020 ◽  
Vol 11 (9) ◽  
pp. 1083
Author(s):  
Luís S. Santos ◽  
Octávia M. Gil ◽  
Susana N. Silva ◽  
Bruno C. Gomes ◽  
Teresa C. Ferreira ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Micronucleus Assay ◽  
Genetic Profile ◽  
Nucleotide Polymorphisms ◽  
Proliferation Capacity ◽  
Non Homologous End Joining ◽  
Well Differentiated ◽  
The Individual

Radioiodine therapy with 131I remains the mainstay of standard treatment for well-differentiated thyroid cancer (DTC). Prognosis is good but concern exists that 131I-emitted ionizing radiation may induce double-strand breaks in extra-thyroidal tissues, increasing the risk of secondary malignancies. We, therefore, sought to evaluate the induction and 2-year persistence of micronuclei (MN) in lymphocytes from 26 131I-treated DTC patients and the potential impact of nine homologous recombination (HR), non-homologous end-joining (NHEJ), and mismatch repair (MMR) polymorphisms on MN levels. MN frequency was determined by the cytokinesis-blocked micronucleus assay while genotyping was performed through pre-designed TaqMan® Assays or conventional PCR-restriction fragment length polymorphism (RFLP). MN levels increased significantly one month after therapy and remained persistently higher than baseline for 2 years. A marked reduction in lymphocyte proliferation capacity was also apparent 2 years after therapy. MLH1 rs1799977 was associated with MN frequency (absolute or net variation) one month after therapy, in two independent groups. Significant associations were also observed for MSH3 rs26279, MSH4 rs5745325, NBN rs1805794, and tumor histotype. Overall, our results suggest that 131I therapy may pose a long-term challenge to cells other than thyrocytes and that the individual genetic profile may influence 131I sensitivity, hence its risk-benefit ratio. Further studies are warranted to confirm the potential utility of these single nucleotide polymorphisms (SNPs) as radiogenomic biomarkers in the personalization of radioiodine therapy.

Postoperative thyroid remnants for differentiated thyroid cancer may not affect the outcome of high-dose radioiodine therapy

Oral Oncology ◽  
2020 ◽  
Vol 104 ◽  
pp. 104610
Author(s):  
Liqin Pan ◽  
Yanying Chen ◽  
Sixiao Li ◽  
Wei Ouyang ◽  
Huijuan Feng ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
High Dose
Sign in / Sign up

Export Citation Format

Share Document